Showing results (691-700 of 744) with videos related to
Sort By:
Pageof 75
Proceedings of the National Academy of Sciences of the United States of America|August 29, 2012
Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcomePaula J Hurley, Luigi Marchionni, Brian W Simons, et al.Plos One|August 2, 2014
Identification of ALK gene alterations in urothelial carcinomaJoaquim Bellmunt, Shamini Selvarajah, Scott Rodig, et al.Cell Communication and Signaling : CCS|September 19, 2019
Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signalingDisharee Nath, Xiang Li, Claudia Mondragon, et al.The American Journal of Surgical Pathology|August 19, 2008
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimensAndrew J Evans, Pauline C Henry, Theodorus H Van der Kwast, et al.Virchows Archiv : an International Journal of Pathology|October 16, 2014
Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologistRodolfo Montironi, Elizabeth H Hammond, Daniel W Lin, et al.Bladder Cancer (Amsterdam, Netherlands)|August 12, 2024
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome AnalysisBurles A Johnson Iii, Benjamin A Teply, Catherine Kagemann, et al.The American Journal of Surgical Pathology|October 23, 2013
Influence of histologic criteria and confounding factors in staging equivocal cases for microscopic perivesical tissue invasion (pT3a): an interobserver study among genitourinary pathologistsVijayalakshmi Ananthanarayanan, Yi Pan, Maria Tretiakova, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanomaSteven A Rosenberg, Richard M Sherry, Kathleen E Morton, et al.Cancer Medicine|February 28, 2015
HER2 as a target in invasive urothelial carcinomaJoaquim Bellmunt, Lillian Werner, Aristotle Bamias, et al.The American Journal of Surgical Pathology|July 28, 2022
Clinicopathologic Spectrum of Secondary Solid Tumors of the Prostate of Nonurothelial Origin: Multi-institutional Evaluation of 85 CasesAndres M Acosta, Jennifer B Gordetsky, Katrina Collins, et al.Pageof 75